Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis

OBJECTIVE: Approximately 30–40% of rheumatoid arthritis (RA) patients who are initially started on low‐dose methotrexate (MTX) will not benefit from the treatment. To date, no reliable biomarkers of MTX inefficacy in RA have been identified. The aim of this study was to analyze whole blood samples f...

Descripción completa

Detalles Bibliográficos
Autores principales: Plant, Darren, Maciejewski, Mateusz, Smith, Samantha, Nair, Nisha, Hyrich, Kimme, Ziemek, Daniel, Barton, Anne, Verstappen, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328381/
https://www.ncbi.nlm.nih.gov/pubmed/30615300
http://dx.doi.org/10.1002/art.40810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328381/
https://www.ncbi.nlm.nih.gov/pubmed/30615300
http://dx.doi.org/10.1002/art.40810

Ejemplares similares